MBX 4291 Phase 1 shows 7% mean weight loss at 8 weeks; MBX 5765 nominated

MBX Biosciences, Inc.

Preliminary blinded data: mean weight loss 7% (range 0-16%) at 8 weeks in first MAD Part B cohort (n=8, incl. 2 placebo).
PK profile supports once-monthly dosing: T1/2Cmax ~26 days, Tmax 13–14 days, dose-proportional PK from 15-180 mg.
MBX 5765 nominated as amycretin prodrug (GLP-1/GIP/GCG/DACRA agonist); IND-enabling studies expected Q2 2026.
Imapextide achieved POC in PBH Phase 2a (glucose nadir +34% at 200 mg); company will not pursue Phase 2b.
12-week MAD Part C data for MBX 4291 remain on track for Q4 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.